Overview
CLB market data
Price History
CLB price chart
Valuation & Profitability
- P/E (TTM)
- 23.34 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.63 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 4.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.79 – $20.36 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $568.5M · P/B 2.81 · P/S 1.10.
Company News
Core Laboratories Q2 Adj. EPS $0.11 Beats $0.09 Estimate, Sales $124.609M Miss $125.100M EstimateBenzinga · Jul 29, 2026, 9:45 PM
Core Laboratories Sees Q3 GAAP EPS $0.12-$0.20 vs $0.16 Est; Sees Sales $128.500M-$135.500M vs $131.330M EstBenzinga · Jul 29, 2026, 9:05 PM
8-K filing — Core Laboratories Inc. /DE/ (CLB)SEC EDGAR · Jul 29, 2026, 8:43 PM
Mobility Global To Replace Core Laboratories Effective Prior To The Opening Of Trading On Thursday, July 2Benzinga · Jun 26, 2026, 9:25 PM